Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

Study Overview
=================
Brief Summary
-----------------
to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China

Detailed Description
-----------------
Hepatopulmonary syndrome (HPS) occurs in approximately 4%-29% of cirrhotic patients and influences mortality. China has 100 million Hepatitis B virus (HBV) carriers and Chronic HBV infection is well-recognized risk factor for cirrhosis.But little is known about the prevalence of HPS in cirrhosis patients caused by HBV in western China. The aim of this study was to investigate the HPS incidence, and the signs, symptoms, arterial blood gas, and BMP9 in the serum of the patients.

Official Title
-----------------
Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

Conditions
-----------------
Hepatopulmonary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18-80 years old; American association of anesthesiologists(ASA) score: I-III; Ability to comply with research programmes; Voluntary participation in the study; Has the history of HBV infection; No primary cardiopulmonary disease (heart disease, emphysema, pneumonia, asthma, etc.) Exclusion Criteria: Severe heart, lung, kidney disease coexisted; American association of anesthesiologists(ASA) score≥IV; forced expiratory volume at one second (FEV1) or forced vital capacity (FVC) <70%, or FEV1 / FVC <0.70; Mental state could not cooperate Absence of written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cirrhosis with HPS<br>Diagnosed as HPS | |
| cirrhosis without HPS<br>Not Diagnosed as HPS | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| transthoracic contrast enhanced echocardiography (CEE) | through the ultrasound to evaluate the imagine of cardiac cavity after intravenous injection of agitated saline | During the operation | 
| arterial blood gas | arterial blood gas analysis was performed through the radial artery. | During the operation | 
| medical history | The medical history was collected through consultation. | During the operation | 
| acropachy | acropachy was examined by inspection | During the operation | 
| spider angioma | spider angioma was examined by inspection | During the operation | 
| liver palms | liver palms was examined by inspection | During the operation | 
| oxygen saturation | oxygen saturation was examined by pulse oximetry | During the operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the content of bone morphogenetic protein (BMP9) in the patients with and without HPS | the content and expression of BMP9 were determined by immunohistochemistry. | 4 to 6 months after the study completion | 
| micro ribonucleic acid 144 (miR144), micro ribonucleic acid 200 (miR200) in the patients with and without HPS | the content and expression of BMP9 were determined by polymerase chain reaction (PCR) | 4 to 6 months after the study completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis B, Chronic, Cirrhosis, Hepatopulmonary Syndrome